Switzerland-based Roche has received approval from the US Food and Drug Administration (FDA) for its Avastin (bevacizumab), in combination with paclitaxel and cisplatin or paclitaxel and topotecan, to treat women with persistent, recurrent or metastatic carcinoma of the cervix.

Avastin is the first biologic medicine approved in combination with chemotherapy, which will help women to live longer than with chemotherapy alone, according to Roche.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Roche chief medical officer and global product development head Dr Sandra Horning said: "With this approval, women with advanced cervical cancer now have the option of Avastin plus chemotherapy to help them live longer than with chemotherapy alone.

"Until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread."

"Cervical cancer is most commonly diagnosed in women between the ages of 35 and 44, and until today, chemotherapy was the only approved treatment option for women whose cancer recurred, persisted or spread."

Avastin was approved in the US to treat five distinct tumour types, with the latest approval for advanced cervical cancer.

See Also:

The approval was granted to treat advanced cervical cancer based on the GOG-0240 study.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The GOG-0240 independent and National Cancer Institute (NCI)-sponsored study of the Gynecologic Oncology Group (GOG), assessed the efficacy and safety profile of Avastin plus chemotherapy (paclitaxel and cisplatin or paclitaxel and topotecan) in women with persistent, recurrent or metastatic cervical cancer.

Roche noted that the study met its primary end-point of improving overall survival with a statistically significant 26% reduction in the risk of death for women who received Avastin plus chemotherapy, compared with those who received chemotherapy alone.

In 2004, the company first received approval for Avastin in the US to treat colorectal cancer.